The hypothalamic-pituitary-adrenal axis and low-dose glucocorticoids in the treatment of septic shock

Pharmacotherapy

Volumn 23, Issue 4, 2003, Pages 514-525

  Williamson, David R ^a   Lapointe, Marc ^b  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTICOAGULANT AGENT; DOPAMINE; DROTRECOGIN; ETOMIDATE; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; KETOCONAZOLE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; PHENOBARBITAL; PHENYTOIN; PLACEBO; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL FUNCTION; ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE COURSE; DOSE RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HEART HEMODYNAMICS; HEMODYNAMIC MONITORING; HORMONE RELEASE; HUMAN; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTENSIVE CARE; META ANALYSIS; NONHUMAN; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; SHOCK, SEPTIC;

EID: 0037380501     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.4.514.32123     Document Type: Review

References (136)

1. Bone RC, Balk RA, Cerra FB, et al. American College of Chest Physicians/Society of Critical Care Medicine consensus conference: definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-55.
2. Matot I, Sprung CL. Definition of sepsis. Intensive Care Med 2001;27:S3-9.
3. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-14.
4. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time? Crit Care Med 1998;26:2078-86.
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
6. Ziegler EJ, Fisher CH, Sprung CL, Straube RC, Sadoff JC, Foulke GE. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1991;324:429-36.
7. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994;121:1-5.
8. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995;23:994-1006.
9. Dhainaut JF, Tenaillon A, Le Tulzo Y. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994;22:1720-8.
10. Fisher CJJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-43.
11. Opal SM, Fisher CJJ, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997;25:1115-24.
12. Fisher CJJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12-21.
13. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934-41.
14. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis. Crit Care Med 1996;24:1431-40.
15. Abraham E, Glauser M, Butler T, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized, controlled, multicenter trial. JAMA 1997;277:1531-8.
16. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet 1998;351:929-33.
17. Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001;29:503-10.
18. Fisher CJJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996;334:1697-702.
19. Reinhart K, Menges T, Gardlund B, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES study. Crit Care Med 2001;29:765-9.
20. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
21. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081-9.
22. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis: the ibuprofen in sepsis study group. N Engl J Med 1997:912-18.
23. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-8.
24. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23:1430-9.
25. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294-303.
26. Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-65.
27. Nasraway SA. Sepsis research: we must change course. Crit Care Med 1999;27:427-30.
28. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-5.
29. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001;29:487-93.
30. Hahn EO, Houser HB, Rammelkamp CH. Effect of cortisone on acute streptococcal infections and post-streptococcal complications. J Clin Invest 1951;30:274-81.
31. Bennett IL, Finland M, Hamburger M, Kass EH, Lepper M, Waisbren BA. The effectiveness of hydrocortisone in the management of severe infections. JAMA 1963;183:462-5.
32. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333-41.
33. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis: results of two double-blind, placebo-controlled trials. N Engl J Med 1988;319:964-71.
34. Odio CM, Faingezicht I, Paris M, et al. The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med 1991;324:1525-31.
35. Montaner JS, Lawson LM, Levitt N, Belzberg A, Schechter MT, Ruedy J. Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990;113:14-20.
36. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a double-blind, placebo-controlled trial. N Engl J Med 1990;323:1444-50.
37. Meduri GU, Headley S, Tolley E, Shelby M, Stentz F, Postlethwaite A. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS. Chest 1995;108:1315-25.
38. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-50.
39. Briegel J. Hydrocortisone and the reduction of vasopressors in septic shock: therapy or only chart cosmetics. Intensive Care Med 2000;26:1723-6.
40. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone to reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999;27:723-32.
41. Bollaert PE. Stress doses of glucocorticoids in catecholamine dependency: a new therapy for a new syndrome. Intensive Care Med 2000;26:3-5.
42. Matot I, Sprung CL. Corticosteroids in septic shock: resurrection of last rites. Crit Care Med 1998;26:627-30.
43. Meduri GU, Kanangat S. Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for reappraisal. Crit Care Med 1998;26:630-3.
44. Briegel J, Forst H, Hellinger H, Haller M. Contribution of cortisol deficiency to septic shock. Lancet 1991;338:507-8.
45. Carlet J. From mega to more reasonable doses of corticosteroids: a decade to recreate hope. Crit Care Med 1999;27:672-4.
46. Meduri GU. New rationale for glucocorticoid treatment in septic shock. J Chemother 1999;11:541-50.
47. Annane D, Raphael JC, Gajdos P. Are endogenous glucocorticoid levels adequate in septic shock? Intensive Care Med 1996;22:711-12.
48. Annane D, Raphael JC, Gajdos P. Steroid replacement in sepsis: an unexplored side of a multifaceted drug class. Crit Care Med 1996;24:899-900.
49. Meduri GU, Chrousos GP. Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way? Chest 1998;114:355-60.
50. Annane D, Sébile V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
51. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;20:1351-62.
52. Bouachour G, Tirot P, Gouello JP, Mathieu E, Vincent JF, Alquier P. Adrenocortical function during septic shock. Intensive Care Med 1995;21:57-62.
53. Cornil A, Copinschi G, Leclercq R, Franckson JR. Cortisol secretion during bacterial infection in man. Acta Endocrinol 1968;58:1-5.
54. Schein RM, Sprung CL, Marcial E, Napolitano L, Chernow B. Plasma cortisol levels in patients with septic shock. Crit Care Med 1990;18:259-63.
55. Zaloga GP, Marik P. Hypothalamic-pituitary-adrenal insufficiency. Crit Care Clin 2001;17:25-41.
56. Beishuizen A, Thijs LG, Vermes I. Patterns of cortisol-binding globulin and the free cortisol index during septic shock and multitrauma. Intensive Care Med 2001;27:1584-91.
57. Saito T, Takanashi M, Gallagher E, et al. Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med 1995;21:204-10.
58. Saito T, Fuse A, Gallagher ET, et al. The effect of methylprednisolone on myocardial beta-adrenergic receptors and cardiovascular function in shock patients. Shock 1996;5:241-6.
59. Lamberts SW, Bruining HA, de Jong FH. Corticosteroid therapy in severe illness. N Engl J Med 1997;337:1285-92.
60. Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency JAMA 2002;287:236-40.
61. Moran JL, Chapman MJ, O'Fathartaigh MS, Peisach AR, Pannall PR, Leppard P. Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock. Intensive Care Med 1994;20:489-95.
62. Aygen B, Inan M, Doganay M, Kelestimur F. Adrenal functions in patients with sepsis. Exp Clin Endocrinol Diabetes 1997;105:182-6.
63. Jurney TH, Cockrell JL, Lindberg JS, Lamiell JM, Wade CE. Spectrum of serum cortisol response to ACTH in ICU patients: correlation with degree of illness and mortality. Chest 1987;92:292-5.
64. Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-45.
65. Span LF, Hermus ARM, Bartelink AKM, et al. Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 1992;18:93-6.
66. Oelkers W. Adrenal insufficiency. N Engl J Med 1996;335:1206-12.
67. Koo DJ, Jackman D, Chaudry IH, Wang P. Adrenal insufficiency during the late stage of polymicrobial sepsis. Crit Care Med 2001;29:618-22.
68. Schroeder S, Wichers M, Klingmüller D, et al. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 2001;29:310-16.
69. Soni A, Pepper GM, Wyrwinski PM, et al. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am J Med 1995;98:266-71.
70. Briegel J, Schelling G, Haller M, Mraz W, Forst H, Peter K. A comparison of the adrenocortical response during septic shock and after complete recovery. Intensive Care Med 1996;22:894-9.
71. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991;337:582-3.
72. Joosten KFM, De Kleijn ED, Westerterp M, et al. Endocrine and metabolic responses in children with meningococcal sepsis: striking differences between survivors and nonsurvivors. J Clin Endocrinol Metab 2000;85:3746-53.
73. van Woensel JBM, Biezeveld MH, Biesterbos Alders AM, et al. Adrenocorticotropic hormone and cortisol levels in relation to inflammatory response and disease severity in children with meningococcal disease. J Infect Dis 2001;184:1532-7.
74. Yamashita S, Drynan J, Guest C, Silverberg J. Comparison of low-dose (1 μg) with conventional-dose cosyntropin (250 μg) for adrenal insufficiency testing in critical illness [abstr]. Crit Care Med 2001;29(suppl):A164.
75. Talwar V, Lodha S, Dash RJ. Assessing the hypothalamic-pituitary-adrenocortical axis using physiological doses of adrenocorticotropic hormone. QJM 1998;91:285-90.
76. Zarkovic M, Ciric J, Stojanovic M, et al. Optimizing the diagnostic criteria for standard (250-μg) and low-dose (1-μg) adrenocorticotropin tests in the assessment of adrenal function. J Clin Endocrinol Metab 1999;84:3170-3.
77. Dökmetas HS, Colak R, Kelestimur F, Selcuklu A, Unluhizarci K, Bayram F. A comparison between the 1-μg adrenocorticotropin (ACTH) test, the short ACTH (250 μg) test, and the insulin tolerance test in the assessment of hypothalamo-pituitary-adrenal axis immediately after pituitary surgery. J Clin Endocrinol Metab 2000;85:3713-19.
78. Dhillo WS, Kong WM, Le Roux CW, et al. Cortisol-binding globulin is important in the interpretation of dynamic tests of the hypothalamic-pituitary-adrenal axis. Eur J Endocrinol 2001;146:231-5.
79. Beishuizen A, Vermes I, Hylkema BS, Haanen C. Relative eosinophilia and functional adrenal insufficiency in critically ill patients. Lancet 1999;353:1675-6.
80. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993;77:1690-4.
81. Perlstein RS, Mougey EH, Jackson WE, Neta R. Interleukin-1 and interleukin-6 act synergistically to stimulate the release of adrenocorticotropic hormone in vivo. Lymphokine Cytokine Res 1991;10:141-6.
82. Perlstein RS, Whitnall MH, Abrams JS, Mougey EH, Neta R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology 1993;132:946-52.
83. Matta SG, Weatherbee J, Sharp BM. A central mechanism is involved in the secretion of ACTH in response to IL-6 in rats: comparison to and interaction with IL-1b. Neuroendocrinology 1992;56:516-25.
84. Lyson K, McCann SM. The effect of interleukin-6 on pituitary hormone release in vivo and in vitro. Neuroendocrinology 1991;54:262-6.
85. Path G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. Clin Endocrinol Metab 1997;82:2343-9.
86. Reincke M, Allolio B, Wurth G, Winkelmann W. The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone. J Clin Endocrinol Metab 1993;77:151-6.
87. Ihle BU. Adrenocortical response and cortisone replacement in systemic inflammatory response syndrome. Anaesth Intensive Care 2001;29:155-62.
88. Zaloga GP. Sepsis-induced adrenal deficiency syndrome. Crit Care Med 2001;29:688-90.
89. Jaattela M, Ilvesmaki V, Voutilainen R, Stenman UH, Saksela E. Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology 1991;128:623-9.
90. Gaillard RC, Turnhill D, Sappino P, Muller AF. Tumor necrosis factor alpha inhibits response of the pituitary gland to hypothalamic releasing factors. Endocrinology 1990;127:101-6.
91. Zhu Q, Solomon S. Isolation and mode of action of rabbit corticostatic (antiadrenocorticotropin) peptides. Endocrinology 1992;130:1413-23.
92. Tominaga T, Fukata J, Hayashi Y, et al. Distribution and characterization of immunoreactive corticostatin in the hypothalamic-pituitary-adrenal axis. Endocrinology 1992;130:1593-8.
93. Catalano RD, Parameswaran V, Ramachandran J, Trunkey DD. Mechanisms of adrenocortical depression during Escherichia coli shock. Arch Surg 1984;119:145-50.
94. Keri G, Parameswaran V, Trunkey DD, Ramachandran J. Effects of septic shock plasma on adrenocortical cell function. Life Sci 1981;28:1917-23.
95. Molijn GJ, Koper JW, van Uffelen JC, et al. Temperature-induced down-regulation of the glucocorticoid receptor in peripheral blood mononuclear leucocyte in patients with sepsis and septic shock. Clin Endocrinol 1995;43:197-203.
96. Kam JC, Szefler SJ, Surs W, et al. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993;151:3460-6.
97. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB. Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol 1991;146:3523-7.
98. Annane D. Corticosteroids for septic shock. Crit Care Med 2001;29:S117-20.
99. Kino T, Chrousos GP. Glucocorticoid and mineralocorticoid resistance/hypersensitivity syndromes. J Endocrinol 2001;169:437-45.
100. Sun X, Fisher DR, Pritts TA, Wray CJ, Hasselgren PO. Expression and binding activity of the glucocorticoid receptor are upregulated in septic muscle. Am J Physiol Regulatory Integrative Comp Physiol 2002;282:R509-18.
101. Molijn GJ, Spek JJ, van Uffelen JCJ, deJong FH, Brinkmann AO, Bruining HA. Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab 1995;80:1799-803.
102. De Bosscher K, Berghe WV, Haegerman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000;109:16-22.
103. Didonato JA, Saatcioglu F, Karin M. Molecular mechanisms of immunosuppression and anti-inflammatory activities by glucocorticoids. Am J Respir Crit Care Med 1996;154:S11-15.
104. Paterson RL, Galley HF, Dhillon JK, Webster NR. Increased nuclear factor κB activation in critically ill patients who die. Crit Care Med 2000;28:1047-51.
105. Bohrer H, Qiu F, Zimmermann T, et al. Role of NFkappaB in the mortality of sepsis. J Clin Invest 1997;100:972-85.
106. Senftleben U, Karin M. The NFκB/IKK pathway. Crit Care Med 2002;30:S18-26.
107. Abraham E. NF-κB activation. Crit Care Med 2000;28:N100-4.
108. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of Ikappa B synthesis. Science 1995;270:286-90.
109. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin ASJ. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
110. De Vera ME, Taylor BS, Wang Q, Shapiro RA, Billiar TR, Geller DA. Dexamethasone suppresses iNOS gene expression by upregulating I-kappa B alpha and inhibiting NF-kappa B. Am J Physiol 1997;273:G1290-6.
111. Beishuizen A, Thijs LG, Haanen C, Vermes I. Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 2001;86:2811-16.
112. Baugh JA, Bucala R. Macrophage migration inhibitory factor. Crit Care Med 2002;30:S27-35.
113. Daun JM, Cannon JG. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IkappaBalpha. Am J Physiol Regul Integr Comp Physiol 2000;279:R1043-9.
114. Briegel J, Kellermann W, Forst H, Haller M, Bittl M, Hoffmann GE. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. Clin Investig 1994;72:782-7.
115. Briegel J, Jochum M, Gippner-Steppert C, Thiel M. Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J Am Soc Nephrol 2001;12:S70-4.
116. Atsuta J, Plitt J, Bochner BS, Schleimer RP. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Am J Respir Cell Mol Biol 1999;20:643-50.
117. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci 1992;89:9991-5.
118. Santini G, Patrignani P, Sciulli MG, et al. The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. Clin Pharmacol Ther 2001;70:475-83.
119. Pleiner J, Heere-Ress E, Langenberger H, et al. Adrenoceptor hyporeactivity is responsible for Escherichia coli endotoxin-induced acute vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 2002;22:95-100.
120. Joulou-Schaeffer G, Gray GA, Fleming I, Schott C, Parrat JR, Stoclet JC. Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 1990;259:H1038-43.
121. Radomski MW, Palmer RMJ, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci 1990;87:10043-7.
122. Katsuyama K, Shichiri M, Kato H, Imai T, Marumo F, Hirata Y. Differential inhibitory actions by glucocorticoid and aspirin on cytokine-induced nitric oxide production in vascular smooth muscle cells. Endocrinology 1999;140:2183-90.
123. Matsumura M, Kakishita H, Suzuki M, Banba N, Hattori Y. Dexamethasone suppresses iNOS gene expression by inhibiting NF-kappaB in vascular smooth muscle cells. Life Sci 2001;69:1067-77.
124. Dandona P, Suri M, Hamouda W, Aljada A, Kumbkarni Y, Thusu K. Hydrocortisone-induced inhibition of reactive oxygen species by polymorphonuclear neutrophils. Crit Care Med 1999;27:2442-4.
125. Bond RF. Peripheral vascular adrenergic depression during hypotension induced by E. coli endotoxin. Adv Shock Res 1983;9:157-69.
126. Landry DW, Oliver JA. Mechanisms of disease: the pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588-95.
127. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002;30:497-500.
128. Bucher M, Hobbhahn J, Taeger K, Kurtz A. Cytokine-mediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am J Physiol Regulatory Integrative Comp Physiol 2002;282:R979-84.
129. van Leeuwen HJ, van der Bruggen T, van Asbeck BS, Boereboom FT. Effect of corticosteroids on nuclear factor-kappa-B activation and hemodynamics in late septic shock. Crit Care Med 2001;29:1074-7.
130. Bellissant E, Annane D. Effect of hydrocortisone on phenylephrine-mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther 2000;68:293-303.
131. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998;46:589-97.
132. Schneider AJ, Voerman HJ. Abrupt hemodynamic improvement in late septic shock with physiological doses of glucocorticoid. Intensive Care Med 1991;17:436-7.
133. Beller BK, Archer LT, Passey RB, Flournoy DJ, Hinshaw LB. Effectiveness of modified steroid-antibiotic therapies for lethal sepsis in the dog. Arch Surg 1983;118:1293-9.
134. Hinshaw LB, Archer LT, Beller-Todd BK, Coalson JJ, Flournoy DJ, Passey R. Survival of primates in LD100 septic shock following steroid/antibiotic therapy. J Surg Res 1980;28:151-70.
135. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM. The effects of high-dose corticosteroids in patients with septic shock: a prospective, controlled study. N Engl J Med 1984;311:1137-43.
136. Lucas CE, Ledgerwood AM. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg 1984;119:537-41.